SNES vs RGEN vs NEOG vs PAHC vs CEVA

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Repligen Corporation at 147. 0x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to -99. 9% for SenesTech, Inc. (SNES). Over 10 years, the gap is even starker: RGEN returned +369. 1% versus SNES's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phibro Animal Health Corporation (PAHC) is the lower-risk stock at 1.

38β versus CEVA, Inc. 's 2. 76β — meaning CEVA is approximately 100% more volatile than PAHC relative to the S&P 500. On balance sheet safety, CEVA, Inc. (CEVA) carries a lower debt/equity ratio of 2% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, SNES leads at 29. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Repligen Corporation (RGEN) is the more profitable company, earning 6.

6% net margin versus -287. 4% for SenesTech, Inc. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -292. 9% for SNES. At the gross margin level — before operating expenses — CEVA leads at 88. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14.

2x forward P/E versus 67. 3x for CEVA, Inc. — 53. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RGEN: 32. 9% to $168. 00.

In this comparison, PAHC (1.

1% yield) pays a dividend. SNES, RGEN, NEOG, CEVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). CEVA, Inc. (CEVA) carries a higher beta of 2. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAHC: +128. 6%, CEVA: +27. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNES (Basic Materials) and RGEN (Healthcare) and NEOG (Healthcare) and PAHC (Healthcare) and CEVA (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SNES is a small-cap high-growth stock; RGEN is a small-cap high-growth stock; NEOG is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock; CEVA is a small-cap quality compounder stock. PAHC pays a dividend while SNES, RGEN, NEOG, CEVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.